Sequential Therapy for Hypogonadotropic Hypogonadism
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The traditional therapy for induction of spermatogenesis in male hypogonadotropic
hypogonadism requires both HCG and human menopausal gonadotropin (HMG) or FSH until pregnancy
occurs. Because of the high cost of hMG or FSH preparations and poor compliance, the
investigators raise a new sequential therapeutic approach which can make the treatment more
economic and tolerable. The zinc supplement will be also evaluated in patients in this study.
This randomized, parallel, open, and multi-center study will compare the efficacy of
traditional therapy with new therapy and evaluate the safety of the new protocol.